As such, the absence of renoprotection in our study should not be viewed as precluding a favourable outcome in kidney disease in individuals with diabetes where a range of non-hemodynamic effects afforded by SGLT2 inhibition may underlie their potential beneficial effects. This evidence concerns the gene SLC5A2 and diabetes mellitus.